SynthesisBMC neurology2017

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.

Abdelrahman Ibrahim Abushouk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.